References
- EvaluatePharma® World Preview 2020, Outlook to 2026 [Internet]. Evaluate; 2020. Report No.: 13th edition. Available from: www.evaluate.com/PharmaWorldPreview2020
- Škalko-Basnet N. Biologics: the role of delivery systems in improved therapy. Biologics. 2014;8:107–114.
- Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32:425–440.
- Li Z, Easton R. Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics. mAbs. 2018;10:18–33.
- Clair-Jones A S, Prignano F, Goncalves J, et al. Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. 2020;7:741–757.
- Patel R, Mehta M, Pipalava P, et al. Insights into human factor studies conducted for US FDA-approved biological combination products. Expert Opin Drug Deliv. 2019;16:1333–1353.
- Hu P, Wang J, Florian J, et al. Systematic review of device parameters and design of studies bridging biologic-device combination products using prefilled syringes and autoinjectors. AAPS J. 2020;22:52.
- Database of licensed biological products (Purple book) [Internet]. Available from: www.fda.gov.https://purplebooksearch.fda.gov/downloads
- US prescribing information, Repatha® (evolocumab) injection, for subcutaneous use, Reference ID 4862676 [Internet]. U.S. Food and Drug Administration; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125522s029s031lbl.pdf
- Clinical pharmacology and biopharmaceutics review, Semglee® (insulin glargine-yfgn), Reference ID 4468057 [Internet]. U.S. Food and Drug Administration; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210605Orig1s000ClinPharmR.pdf
- Clinical Pharmacology Review, Abrilada® (adalimumab-afzb), Reference ID 4520981 [Internet]. U.S. Food and Drug Administration; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761118Orig1s000MultidisciplineR.pdf
- Cox DS, Alvarez DF, Bock AE, et al. Randomized, open-label, single-dose, parallel group pharmacokinetic study of PF-06410293 (Adalimumab-afzb), an adalimumab biosimilar, by subcutaneous dosing using a prefilled syringe or a prefilled pen in healthy subjects. Clin Pharmacol Drug Dev. 2021;10:1166–1173.
- Fettner S, Mela C, Wildenhahn F, et al. Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector. Expert Opin Drug Deliv. 2019;16:551–561.
- Clinical Pharmacology and Biopharmaceutics Review, Aimovig® (erenumab) subcutaneous injection, Reference ID 4224222 [Internet]. U.S. Food and Drug Administration; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761077Orig1s000ClinPharmR.pdf
- Cherniakov I, Cohen-Barak O, Tiver R, et al. A pharmacokinetic bioequivalence study of fremanezumab administered subcutaneously using an autoinjector and a prefilled syringe. Clin Pharmacol Drug Dev. 2021;10:1018–1027.
- Struemper H, Murtaugh T, Gilbert J, et al. Relative bioavailability of a single dose of belimumab administered subcutaneously by prefilled syringe or autoinjector in healthy subjects. Clin Pharmacol Drug Dev. 2016;5:208–215.
- Clinical Pharmacology and Biopharmaceutics Review, Benlysta® (belimumab), Reference ID 4113048 [Internet]. U.S. Food and Drug Administration; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761043Orig1s000ClinPharmR.pdf
- Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers (NCT00813774) [Internet]. 2013. Available from: https://clinicaltrials.gov/ct2/show/NCT00813774
- Clinical Pharmacology and Biopharmaceutics Review, Cosentyx® (secukinumab) subcutaneous injection, Reference ID 3671340 and 3622771 [Internet]. U.S. Food and Drug Administration; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125504Orig1s000ClinPharmR.pdf
- Bruin G, Hockey H-UP, Stella PL, et al. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients. Br J Clin Pharmacol. 2020;86:338–351.
- Stauffer VL, Sides R, Lanteri-Minet M, et al. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer Adherence. 2018;12:1785–1795.
- Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects (NCT02588534) [Internet]. 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02588534
- Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection (NCT02799498) [Internet]. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02799498
- Clinical Pharmacology and Biopharmaceutics Review, Erelzi® (etanercept-szzs), Reference ID 3963191 [Internet]. U.S. Food and Drug Administration; 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761042Orig1s000ClinPharmR.pdf
- Martin UJ, Fuhr R, Forte P, et al. Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results. J Asthma. 2021;58:93–101.
- Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers (NCT02968914) [Internet]. cited 2022 Jan 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02968914
- Shin D, Lee Y, Jeong D, et al. Comparative pharmacokinetics of an Adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects. Drug Des Devel Ther. 2018;12:3799–3805.
- Bush J, Kawakami K, Muniz R. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects. BMC Pharmacol Toxicol. 2019;20:87.
- Clinical Pharmacology and Biopharmaceutics Review, Hyrimoz® (adalimumab-adaz), Reference ID 4285886 [Internet]. U.S. Food and Drug Administration; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761071Orig1s000ClinPharmR.pdf
- von Richter O, Lemke L, Haliduola H, et al. GP2017, an Adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. Expert Opin Biol Ther. 2019;19:1075–1083.
- A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients (NCT03560739) [Internet]. [cited 2022 Jan 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT03560739
- Kivitz A, Baret-Cormel L, van Hoogstraten H, et al. Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2018;5:231–242.
- Clinical Pharmacology and Biopharmaceutics Review, Neulasta® (pegfilgrastim), Reference ID 3628157 [Internet]. U.S. Food and Drug Administration; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125031Orig1s181.pdf
- Yang -B-B, Morrow PK, Wu X, et al. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemother Pharmacol. 2015;75:1199–1206.
- Clinical Pharmacology Review, Nucala® (Mepolizumab), Reference ID 4443018 [Internet]. U.S. Food and Drug Administration; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761122Orig1s000MultidisciplineR.pdf
- Shabbir S, Pouliquen IJ, Bentley JH, et al. The pharmacokinetics and relative bioavailability of mepolizumab 100 mg liquid formulation administered subcutaneously to healthy participants: a randomized trial. Clin Pharmacol Drug Dev. 2020;9:375–385.
- Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe (NCT01890473) [Internet]. [cited 2022 Jan 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT01890473
- Clinical Pharmacology and Biopharmaceutics Review, Plegridy® (pegylated interferon beta-1a), Reference ID 3605128 and 3441168 [Internet]. U.S. Food and Drug Administration; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125499Orig1s000ClinPharmR.pdf
- Clinical Pharmacology and Biopharmaceutics Review, Repatha® (evolocumab) Reference ID 3772601 [Internet]. U.S. Food and Drug Administration; 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125522Orig1s000ClinPharmR.pdf
- Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen (NCT01849497) [Internet]. cited 2022 Feb 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT01849497
- Dent R, Joshi R, Djedjos CS, et al. Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. Springerplus. 2016;5. DOI:10.1186/s40064-016-1892-3.
- Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen (NCT01879319) [Internet]. cited 2022 Feb 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT01879319
- Clinical Pharmacology and Biopharmaceutics Review, Simponi® (golimumab) [Internet]. U.S. Food and Drug Administration; 2009. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125289s000_ClinPharmR_P1.pdf
- Lon H-K, Cheng L, Nudurupati S, et al. Pharmacokinetic comparability of risankizumab formulations in prefilled syringe and auto-injector for subcutaneous injection. Clin Ther. 2021;43:629–636.
- Clinical Pharmacology and Biopharmaceutics Review, Taltz® (ixekizumab), Reference ID 3841002 [Internet]. U.S. Food and Drug Administration; 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000ClinPharmR.pdf
- Duffin KC, Bagel J, Bukhalo M, et al. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017;31:107–113.
- A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects (PATH-BRIDGE) (NCT03989544) [Internet]. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03989544
- Clinical Pharmacology Review, Tezspire® (tezepelumab-ekko), Reference ID 4906971 [Internet]. U.S. Food and Drug Administration; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761224Orig1s000MultidisciplineR.pdf
- Clinical Pharmacology Review, Xolair® (Omalizumab), Reference ID 4326577 [Internet]. U.S. Food and Drug Administration; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/103976Orig1s5231.pdf
- Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerations (draft guidance) [Internet]. U.S. Food and Drug Administration; 2014. Available from: https://www.fda.gov/media/88254/download
- Statistical Approaches to Establishing Bioequivalence (Guidance for Industry) [Internet]. U.S. Food and Drug Administration; 2001. Available from: https://www.fda.gov/media/70958/download
- US prescribing information, Abrilada® (adalimumab-afzb) injection, for subcutaneous use, Reference ID 4520989 [Internet]. U.S. Food and Drug Administration; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761118s000lbl.pdf
- US prescribing information, Emgality® (galcanezumab-gnlm) injection, for subcutaneous use, Reference ID 4526735 [Internet]. U.S. Food and Drug Administration; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761063s004lbl.pdf
- US prescribing information, Dupixent® (dupilumab) injection, for subcutaneous use, Reference ID 4908826 [Internet]. U.S. Food and Drug Administration; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761055s021s027s033lbl.pdf
- US prescribing information, Hulio® (adalimumab-fkjp) injection, for subcutaneous use, Reference ID 4636419 [Internet]. U.S. Food and Drug Administration; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761154s000lbl.pdf
- US prescribing information, Humira® (adalimumab) injection, for subcutaneous use, Reference ID 4751984 [Internet]. U.S. Food and Drug Administration; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf
- US prescribing information, Hyrimoz® (adalimumab-adaz) injection, for subcutaneous use, Reference ID 4752382 [Internet]. U.S. Food and Drug Administration; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761071s001lbl.pdf
- US prescribing information, Taltz® (ixekizumab) injection, for subcutaneous use, Reference ID 4759462 [Internet]. U.S. Food and Drug Administration; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125521s014lbl.pdf
- US prescribing information, Ajovy® (fremanezumab-vfrm) injection, for subcutaneous use, Reference ID 4862358 [Internet]. U.S. Food and Drug Administration; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761089s013lbl.pdf
- US prescribing information, Herceptin Hylecta® (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use [Internet]. U.S. Food and Drug Administration; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106Orig1s000lbl.pdf
- US prescribing information, Rituxan Hycela® (rituximab and hyaluronidase human) injection, for subcutaneous use [Internet]. U.S. Food and Drug Administration; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761064s013lbl.pdf
- Patel R, Mehta M, Dahiya M, et al. A review of use errors reported in human factor validation studies of biological combination products. J Med Eng Technol. 2021;45:582–592.
- Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab. 2010;36(Supplement 2):S3–S18.
- Bridging for Drug-Device and Biologic-Device Combination Products (Draft Guidance for Industry) [Internet] . U.S. Food and Drug Administration; 2019. Available from: https://www.fda.gov/media/133676/download
- Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (guidance for industry) [Internet]. U.S. Food and Drug Administration; 2016. Available from: https://www.fda.gov/media/88622/download
- Chen ML, Lee SC, Ng MJ, et al. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther. 2000;68(5):510–521.
- Singh I, Attrey A, Garg A, et al. Single dose pharmacokinetics, pharmacodynamics and immunogenicity, and multiple dose immunogenicity of INTP5 (Pegfilgrastim biosimilar) versus reference pegfilgrastim in healthy subjects. Clin Drug Investig. 2021;41:29–42.
- Immunogenicity assessment for therapeutic protein products (guidance for industry) [Internet]. U.S. Food and Drug Administration; 2014. Available from: https://www.fda.gov/media/85017/download
- Singh I, Patel A, Patel R, et al. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects. Cancer Chemother Pharmacol. 2018;82(2):329–337.